Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab

BACKGROUND: The safety of pembrolizumab monotherapy in treatment‐naïve non‐small cell lung cancer (NSCLC) patients with high programed death‐ligand 1 (PD‐L1) expression and pre‐existing interstitial lung disease (ILD) has not yet been determined. Here, we aimed to evaluate the prognosis, efficacy an...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamaguchi, Ou, Kaira, Kyoichi, Shinomiya, Shun, Mouri, Atsuto, Hashimoto, Kosuke, Shiono, Ayako, Miura, Yu, Akagami, Tomoe, Imai, Hisao, Kobayashi, Kunihiko, Kagamu, Hiroshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862785/
https://www.ncbi.nlm.nih.gov/pubmed/33185333
http://dx.doi.org/10.1111/1759-7714.13725

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7862785/
https://www.ncbi.nlm.nih.gov/pubmed/33185333
http://dx.doi.org/10.1111/1759-7714.13725

Ejemplares similares